Literature DB >> 8639172

Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion.

N Del Papa1, L Guidali, M Sironi, Y Shoenfeld, A Mantovani, A Tincani, G Balestrieri, A Radice, R A Sinico, P L Meroni.   

Abstract

OBJECTIVE: To elucidate the role of anti-endothelial cell antibodies (AECA) in vascular inflammation in patients with Wegener's granulomatosis (WG).
METHODS: IgG fractions from 3 AECA-positive WG patients, IgG from 3 AECA-negative WG patients, and IgG from healthy donors were tested for their ability to: a) bind to endothelial cells and to display complement-dependent or antibody-dependent cellular cytotoxicity, b) modulate cell membrane expression of adhesion molecules, as evaluated by cytofluorometry and by immunoenzymatic assay, and c) induce the secretion of interleukin-1 beta (IL-1 beta), IL-6, IL-8, and monocyte chemotactic protein 1 (MCP-1).
RESULTS: We found that AECA IgG from WG patients do not display any significant cytotoxicity but are able to up-regulate the expression of E-selectin, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 and to induce the secretion of IL-1 beta, IL-6, IL-8, and MCP-1.
CONCLUSION: AECA in patients with WG could play a potential pathogenetic role by activating endothelial cells, and thus facilitating leukocyte recruitment and adhesion to endothelial surfaces, rather than by displaying a cytotoxic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639172     DOI: 10.1002/art.1780390507

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations.

Authors:  Laura B Hughes; S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

3.  Functional heterogeneity of anti-endothelial cell antibodies.

Authors:  A Bordron; R Révélen; F D'Arbonneau; M Dueymes; Y Renaudineau; C Jamin; P Youinou
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 4.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

5.  Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Authors:  M M Boomsma; D J Stearns-Kurosawa; C A Stegeman; E Raschi; P L Meroni; S Kurosawa; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

6.  Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway.

Authors:  Y-H Yang; Y-H Huang; Y-L Lin; L-C Wang; Y-H Chuang; H-H Yu; Y-T Lin; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

7.  Anti-endothelial cell antibodies in rheumatic heart disease.

Authors:  V Scalzi; H Abu Hadi; C Alessandri; C Croia; V Conti; L Agati; A Angelici; V Riccieri; C Meschini; A Al-Motarreb; A Al-Ansi; G Valesini
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 8.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

9.  Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.

Authors:  M De Bandt; O Meyer; L Dacosta; C Elbim; C Pasquier
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 10.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.